An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics

Dulaglutide (dula, LY2189265) is a once-weekly glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus. An adaptive, dose-finding, inferentially seamless phase 2/3 study was designed to support the development of this novel diabetes therapeutic. The study is divid...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Geiger, Mary Jane, Skrivanek, Zachary, Gaydos, Brenda, Chien, Jenny, Berry, Scott, Berry, Donald, Anderson, James H.
Formáid: Artigo
Teanga:Inglês
Foilsithe: Diabetes Technology Society 2012
Ábhair:
Symposium
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570871/
https://ncbi.nlm.nih.gov/pubmed/23294776
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla